PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (August 2026)
36 slides from PetVivo's investor presentation, Aug 20, 2026
Slide 1: Investor Presentation August 2026
Investor Presentation August 2026 PETV (OTCQX)
Slide 2: Forward-Looking Statements
Forward-Looking Statements PETYIVO This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially fr
Slide 3: PetVivo - Subsidiaries Org Chart
PetVivo - SubsidiariesOrgChart @S)PETYIVO PetVivo Holdings, Inc. (PETV) 31© PetVivo: Confidential and Proprietary
Slide 4: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary care and product sales market with ~ 6% historical CAGR (2020-2024)* Commercial Platform + Next-Generation Product Pipel Spryng®, with OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint
Slide 5: Osteoarthritis (OA) Opportunity
Osteoarthritis (OA) Opportunity $39.8B Veterinary Care and Product Sales Market Osteoarthritis: Current solutions treat a common affliction symptoms, but do not of the joints manage the cause e Affects approximately 34 million ¢ Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) adult dogs and 1 million
Slide 6: Viscosupplementation
Viscosupplementation A strong hydrated biomaterial that facilitates enhanced Lubrication and joint-cushioning properties. & Micro-scaffolds Over time, micro-scaffolds adhere to and integrate with the existing synovial membrane. Collagen-Elastin Microparticles Porous, spongy particles absorb and rele
Slide 7: An Optimal OA Solution: Spryng with OsteoCushion Technology
An Optimal OA Solution: Spryng® with OsteoCushion® Technology Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function o Similar components/function found in natural cartilage (i.e. collagen, elastin and hepa
Slide 8: Spryng with OsteoCushion Technology
Spryng® with OsteoCushion® Technology e Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms e Purified natural components self-assemble to form an insoluble, hydrated matrix e Protein source bovine tissues (i.e. medical grade collagen and elastin)
Slide 9: Spryng Mechanism of Action
Spryng® Mechanism of Action e Ananimal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain, and further loss of cartilage e Spryng reinforces synovial membrane function, without p
Slide 10: Spryng Canine Success: Koda
Sean or click to read Koda’s story Spryng® Canine Success: Koda Condition Treatment 4-year-old FS Labrador Retriever e Koda developed a persistent front limb limp following falls in July and September 2023. e Koda’s rehabilitation team recommended Spryng as an option to help address her ongoing elbo
Slide 11: Spryng Equine Success: Red
Scan or click to read Red’s story Spryng® Equine Success: R History reatmen Results! 26-year-old Quarter Horse e Redrema | pa and e Day 1: That evening, gelding n Red was observed S y trotting to greet his Red was diagnosed with O gt ora owner. severe ringbone and bone- ifferent appr Day 3: Red’ bil
Slide 12: Spryng Canine Success: Pratchett
Spryng® Canine Success: Pratchett Scan or click to read Pratchett's story Condition Treatment 7-year-old MN Smoke Tabby Shorthair Pratchett developed right hind limb lameness and pelvic discomfort, eventually becoming unable to jump onto the bed or couch. Examination revealed right stifle instabilit
Slide 13: Spryng Competitive Distinctions
Spryng® Competitive Distinctions @ Outcomes address affliction/not just symptoms e Current treatments rely on biologic activity to treat symptoms; Spryng provides structural components to address affliction Price/Cost advantage Derived from all natural materials Ease of application Vet clinic exclus
Slide 14: Spryng Product Comparison
Spryng® Product C Features Librela Solensia Adequan HA/Legend Injections per Year 12 16-18 NIA Benefits Last up to 12 Months or More Bioscaffold From Naturally-Derived Components No Synthetic or Radioactive Material Research Supports Joints Health Benefits No Drug Interactions & No Systemic Effects
Slide 15: Spryng Tolerance Studies
Spryng® Tolerance Studies Canine Tolerance Purpose: Assess tolerance of Spryng® administration in dogs. Design: 20 healthy dogs received intra-articular injection with saline or Spryng@ in contralateral shoulder, hip, elbow, and stifle joints in a randomized sequence. Two-week washout period transpi
Slide 16: Spryng Clinical Studies
Spryng® Clinical Studies CanineHipOA CASE ETHOS Purpose: Study the effects of Collagen-Elastin Hydrogel Microparticles (Spryng) on pain & function secondary to hip osteoarthritis in dogs. Investigators: Colorado Animal Specialty & Emergency with Ethos Veterinary Health Design: Using Simon's Two-Stag
Slide 17: Spryng Peer-Reviewed Studies
Spryng® Peer-Reviewed Studies Equine Joint Inflammation Purpose: Evaluate whether Collagen-Elastin Hydrogel Microparticles (CEHM) affect inflammatory responses in equine cartilage and synovial membrane exposed to inflammatory cytokines. Investigators: Cornell University College of Veterinary Medicin
Slide 18: New Spryng Clinical Trials
New Spryng® Clinical Trials Underway or Recently Completed, Awaiting Publication Canine Study at Colorado State University Principal investigators: Felix Duerr, DVM, MS, Dr. med. vet., CCRT, DACVS-SA, DECVS, DACVSSMR Pilot study design: Pilot study evaluating intra-articular injection of a hydrophil
Slide 19: Functional Biomaterials Platform (CEHM + Piezoelectric Fibers)
Functional Biomaterials Platform (CEHM + Pieoelectric Fibers) Two Complementary Technologies. One Responsive Intra-Articular Platform. @ Cell-Free & Drug-Free Innovation: Combines PetVivo's proprietary collagen-elastin hydrogel microparticle (CEHM) technology with embedded piezoelectric nanofibers t
Slide 20: Potential Applications for Functional Biomaterials in Veterinary Medicine
Potential Applications for Functional Biomaterials in Veterinary Medicine Respiratory and Airway Wound Healing Post Surgical Healing Ophthalmic Uses e Corneal Ulceration e Keratoconjunctivitis Sicca e Descemetocele Dental and Oral Surgical Procedures Musculoskeletal Disease/Injury © Osteoarthritis e
Slide 21: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities e Spryng® product is manufactured in PetVivo's ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 e Initial batch sizes of approx. 500 syringes; planning to increase to batches of 5,000+ syringes per month. e Current production facility annual capacity is approx
Slide 22: Comprehensive IP Portfolio
Comprehensive IP Portfolio e 10 US and Foreign Issued Patents and 2 additional pending Broad Claim Language - “Comprising” Transitions 6 Detailed Proprietary Trade Secrets e Our Patents & Trade Secrets Protect: Protein & Carbohydrate Based Thermoplastics Biomaterials of Many Compositions Medical, Dr
Slide 23: Market Overview
Sources: American Pet Products Assoc.; North M ar ket Ove ‘Vv i ew American Pet Health Insurance Association, American Horse Council, LendEDU Companion Animal/Veterinarian * Agricultural and professional equine markets not included e US Pet Spend increased from $152B in 2024 to $157B in 2025 e Veter
Slide 24: Animal Product Pipeline
Animal Product Pipeline FDA clearance not required VD-01 VD-02 VD-03 VD-04 VD-05 VD-06 VD-07 VD-08 Osteoarthritis Osteoarthritis Osteoarthritis Ocular Care Osteoarthritis Wound Care Respiratory Indications babel aia * Canine, Equine, Feline Mucoadhesive Devices 24 1© PetVivo: Confidential and Propri
Slide 25: Human Product Pipeline
H uman Prod uct Pipel ine FDA Review or Clearance Required for Commercialization of Human Medical Devices FDA clearance required HD-01 Osteoarthritis Human (Spryng@) TBD HD-02 Osteoarthritis Human (Revivion™) = TBD Human nib» Coutanicare (Spryng@/Revivion™) » = Human Bey | Mb puiedieate (Spryng@/Rev
Slide 26: Distribution Partners
Distribution Partners MWI Animal Heal cencora MWI Animal Health MWI - PetVivo Distribution Services Agreement Terms: e Non-exclusive distribution agreement with ongoing annual renewal option until terminated by either party MWI Overview: e@ One of largest distributors of veterinary products in the w
Slide 27: Distribution Partners Cont.
Distribution Partners Cont. Patterson Veterinary — PetVivo Distribution Patterson Veterinary Services Agreement Terms: Non-exclusive distribution agreement with ongoing annual renewal option until terminated by either party Patterson Veterinary Overview: One of the largest distributors serving compa
Slide 28: Wholesale Partners
Wholesale Partners Vedco — Wholesaler Engagement: e Wholesaler relationship to purchase product from PetVivo and sell it to national distributors for subsequent sale to U.S. vets e Designated wholesaler for PetVivo's veterinary medical device, Spryng® with OsteoCusion® Technology Vedco Overview: e V
Slide 29: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Exclusive White Label License Relationship: Exclusive white label license agreement between PetVivo and Digital Landia for the AgenticPet™ Al B2B platform. PetVivo holds exclusive commercialization and deployment rights in veterinary market
Slide 30: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Current Development Status and Third-Party Validation e Core multi-agent architecture completed and operating in controlled beta environments. e Secure API integrations and modular deployment framework finalized for B2B partners. e Ongoing
Slide 31: PetVivo Strategic Partners
PetVivo Strategic Partners PiezoBioMembrane, Inc. (“PBM”) and Veterinary Growth Partners (“VGP”)
Slide 32: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience . » ) Bryan Monninger Josh Wilhelm VP of Operations & RED John Lai Garry Lowenthal John F. Dolan CEO, President & Director CFO General Counsel VP of Sales & Distributor Relations = ArRAusT Novus €p 2A HEALTH pwe
Slide 33: Strong Independent Board of Directors and Advisors
Strong Independent Board of Directors and Advisors @ 8 8 9 Advisors Dr. Tracy Turner, DVM, MS, Dipl. ACVS, Dipl. ACSMR, Amer. Academy Thermology, AAEP Board Dr. Sherman Cannap, DVM, MS, CCRT, DACVS-SA, DACVSMER, Cannap Sports Medicine, Orthobiologic Innovations Dr. Debra Cannap, DVM, CCRT, CVA, DACV
Slide 34: Growth Drivers
Growth Drivers Sales Growth & Expansion e US Direct Veterinary Sales Force e 100% US veterinary market coverage via established distributor network. e International expansion; UK/MX (2025) CA (Q2 2026); EU expected CY2026. e Momentum and growth in clinic adoption and use cases delivering ~ 17% incre
Slide 35: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary care and product sales market with ~ 6% historical CAGR (2020-2024)* Spryng®, with OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint mechanics for the management of lameness and other j
Slide 36: John Lai, Chief Executive Officer
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 Spryng® with OsteoCushion® Technology is exclusively sold and distributed by PetVivo Animal Health. Veterinary Use Only - Federal law restricts this device to use by or on the order of a licensed veterinarian. 844-Pet-Vivo (844-738-848
PetVivo Holdings — Investor Presentation (August 2026) on 6ix